SA’s biggest pharmaceutical manufacturer Aspen Pharmacare is on the hunt for acquisitions to help it grow its business in emerging markets, after slashing its debt with a series of disposals that concluded this week with Mylan’s acquisition of the commercial rights to its European thrombosis business for €641.9m (R12.7bn).   

Aspen CEO Stephen Saad said the company was seeking “bolt-on” rather than transformative acquisitions, and would be looking to buy products to add to its portfolios in the territories it already operated in, which include SA, China, Latin America and Australia.

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, ProfileData financial data, and digital access to the Sunday Times and Sunday Times Daily.

Already subscribed? Simply sign in below.



Questions or problems? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now